You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

497 Results
Regimen
Intent: Adjuvant
Funding:
ODB - General Benefit
    anastrozole
Dec 2025
Statistical Reports
Les statistiques sur le cancer en Ontario 2024 représentent le cinquième d'une série de rapports qui fournissent des informations approfondies sur l'...
Feb 2025
Guidelines and Advice
Status: In-Review
ID: 4-17
Version: 2
Jan 2018
Regimen
Cancer Type:
Hematologic, 
Lymphoma - Hodgkin
Intent: Curative
Funding:
New Drug Funding Program
    Nivolumab - In Combination with Chemotherapy for Previously Untreated Advanced Stage Hodgkin Lymphoma
Dec 2025
Drug
Other Name(s): Rybrevant®
Dec 2025
Regimen
Cancer Type:
Lung, 
Non-Small Cell
Intent: Palliative
Funding:
Exceptional Access Program
    alectinib - Treatment of ALK-positive locally advanced or metastatic non-small cell lung cancer, according to specific criteria
Dec 2025
Regimen
Cancer Type:
Hematologic, 
Leukemia - Chronic Myeloid (CML)
Intent: Palliative
Funding:
Exceptional Access Program
    asciminib - For the treatment of Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase, based on criteria
Dec 2025
Drug
Other Name(s): Calquence®
Dec 2025
Drug
Other Name(s): Verzenio®
Dec 2025
Drug
Other Name(s): Arimidex®
Dec 2025
Regimen
Intent: Palliative
Dec 2025

Pages